Is AI Biased Toward "Exceptional Responders?"
Source: Clinical Leader
Ram Mukunda of IGC Pharma poses a question to Michael Lingzhi Li of Harvard about the risks of using AI to identify only on a small subset of patients who would then be enrolled in a clinical trial.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more